16-9841079-C-T

Variant summary

Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBP6BS1

The NM_001134407.3(GRIN2A):​c.1354G>A​(p.Val452Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000167 in 1,613,836 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.00098 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000082 ( 1 hom. )

Consequence

GRIN2A
NM_001134407.3 missense

Scores

1
6
12

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:6

Conservation

PhyloP100: 1.57

Publications

4 publications found
Variant links:
Genes affected
GRIN2A (HGNC:4585): (glutamate ionotropic receptor NMDA type subunit 2A) This gene encodes a member of the glutamate-gated ion channel protein family. The encoded protein is an N-methyl-D-aspartate (NMDA) receptor subunit. NMDA receptors are both ligand-gated and voltage-dependent, and are involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. These receptors are permeable to calcium ions, and activation results in a calcium influx into post-synaptic cells, which results in the activation of several signaling cascades. Disruption of this gene is associated with focal epilepsy and speech disorder with or without cognitive disability. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014]
GRIN2A Gene-Disease associations (from GenCC):
  • complex neurodevelopmental disorder
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • Landau-Kleffner syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
  • continuous spikes and waves during sleep
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutation
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • rolandic epilepsy-speech dyspraxia syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • self-limited epilepsy with centrotemporal spikes
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • neurodevelopmental disorder
    Inheritance: AR Classification: LIMITED Submitted by: G2P

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -9 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.010441124).
BP6
Variant 16-9841079-C-T is Benign according to our data. Variant chr16-9841079-C-T is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 205649.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.000985 (150/152294) while in subpopulation AFR AF = 0.00337 (140/41572). AF 95% confidence interval is 0.00291. There are 0 homozygotes in GnomAd4. There are 68 alleles in the male GnomAd4 subpopulation. Median coverage is 31. This position passed quality control check.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GRIN2ANM_001134407.3 linkc.1354G>A p.Val452Met missense_variant Exon 6 of 13 ENST00000330684.4 NP_001127879.1 Q12879-1Q547U9Q59EW6

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GRIN2AENST00000330684.4 linkc.1354G>A p.Val452Met missense_variant Exon 6 of 13 1 NM_001134407.3 ENSP00000332549.3 Q12879-1

Frequencies

GnomAD3 genomes
AF:
0.000979
AC:
149
AN:
152176
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00335
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000458
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00144
GnomAD2 exomes
AF:
0.000239
AC:
60
AN:
250998
AF XY:
0.000147
show subpopulations
Gnomad AFR exome
AF:
0.00314
Gnomad AMR exome
AF:
0.000203
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00000882
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.0000821
AC:
120
AN:
1461542
Hom.:
1
Cov.:
33
AF XY:
0.0000633
AC XY:
46
AN XY:
727096
show subpopulations
African (AFR)
AF:
0.00290
AC:
97
AN:
33464
American (AMR)
AF:
0.000224
AC:
10
AN:
44706
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26132
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39670
South Asian (SAS)
AF:
0.00
AC:
0
AN:
86250
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53410
Middle Eastern (MID)
AF:
0.000173
AC:
1
AN:
5768
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
1111766
Other (OTH)
AF:
0.000182
AC:
11
AN:
60376
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.479
Heterozygous variant carriers
0
8
16
23
31
39
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000985
AC:
150
AN:
152294
Hom.:
0
Cov.:
31
AF XY:
0.000913
AC XY:
68
AN XY:
74464
show subpopulations
African (AFR)
AF:
0.00337
AC:
140
AN:
41572
American (AMR)
AF:
0.000458
AC:
7
AN:
15296
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3466
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5174
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4834
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10608
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
68026
Other (OTH)
AF:
0.00142
AC:
3
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.490
Heterozygous variant carriers
0
8
17
25
34
42
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000311
Hom.:
1
Bravo
AF:
0.00114
ESP6500AA
AF:
0.00341
AC:
15
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.000296
AC:
36

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:6
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:1Benign:2
Aug 01, 2023
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

GRIN2A: PS4:Supporting, BS1 -

Aug 02, 2019
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 25904555, 22833210, 26283219, 27839871) -

Oct 12, 2017
Eurofins Ntd Llc (ga)
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
Apr 25, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

GRIN2A-related disorder Benign:1
May 16, 2022
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Landau-Kleffner syndrome Benign:1
Jan 20, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Dec 18, 2018
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.12
BayesDel_addAF
Benign
-0.36
T
BayesDel_noAF
Benign
-0.29
CADD
Benign
21
DANN
Uncertain
1.0
DEOGEN2
Benign
0.27
T;.;.;T
Eigen
Benign
0.11
Eigen_PC
Uncertain
0.26
FATHMM_MKL
Uncertain
0.94
D
LIST_S2
Uncertain
0.91
.;D;D;D
M_CAP
Uncertain
0.10
D
MetaRNN
Benign
0.010
T;T;T;T
MetaSVM
Benign
-0.99
T
MutationAssessor
Benign
1.1
L;.;L;L
PhyloP100
1.6
PrimateAI
Pathogenic
0.82
D
PROVEAN
Benign
-1.5
N;.;N;N
REVEL
Benign
0.13
Sift
Benign
0.11
T;.;T;T
Sift4G
Uncertain
0.047
D;T;T;D
Polyphen
0.97
D;.;.;D
Vest4
0.41
MVP
0.38
MPC
1.2
ClinPred
0.075
T
GERP RS
5.6
Varity_R
0.33
gMVP
0.76
Mutation Taster
=5/95
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs145956175; hg19: chr16-9934936; COSMIC: COSV58059126; API